ROCKVILLE, Md., Oct. 04, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative
RNS Number : 4224O MaxCyte, Inc. 02 October 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, Maryland - 2 October 2023: MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform
RNS Number : 3508M MaxCyte, Inc. 13 September 2023 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 1986M MaxCyte, Inc. 12 September 2023 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support
RNS Number : 5613L MaxCyte, Inc. 06 September 2023 MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing ROCKVILLE, MD , September 6, 2023 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
RNS Number : 4644L MaxCyte, Inc. 05 September 2023 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
ROCKVILLE, Md., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development
RNS Number : 4254L MaxCyte, Inc. 05 September 2023 MaxCyte to Participate in Baird Global Healthcare Conference Rockville, MD , September 5, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to
RNS Number : 3137L MaxCyte, Inc. 04 September 2023 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
